211 related articles for article (PubMed ID: 26248529)
1. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients.
Feinstein JA; Feudtner C; Valuck RJ; Kempe A
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1049-57. PubMed ID: 26248529
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy.
Slabaugh SL; Maio V; Templin M; Abouzaid S
Drugs Aging; 2010 Dec; 27(12):1019-28. PubMed ID: 21087071
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Chronic Multiclass Psychotropic Polypharmacy and Psychotherapy in Foster Care Youth in a State Medicaid Population.
Keast SL; Tidmore LM; Shropshire D; Nesser N; Lambert TL
J Manag Care Spec Pharm; 2019 Dec; 25(12):1340-1348. PubMed ID: 31778625
[TBL] [Abstract][Full Text] [Related]
4. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals.
Feinstein J; Dai D; Zhong W; Freedman J; Feudtner C
Pediatrics; 2015 Jan; 135(1):e99-108. PubMed ID: 25511114
[TBL] [Abstract][Full Text] [Related]
5. Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis.
Rizkalla NA; Feudtner C; Dai D; Zuppa AF
Pediatr Crit Care Med; 2013 Nov; 14(9):e394-403. PubMed ID: 23965636
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.
Dai D; Feinstein JA; Morrison W; Zuppa AF; Feudtner C
Pediatr Crit Care Med; 2016 May; 17(5):e218-28. PubMed ID: 26959349
[TBL] [Abstract][Full Text] [Related]
7. Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children.
Kreider AR; Matone M; Bellonci C; dosReis S; Feudtner C; Huang YS; Localio R; Rubin DM
J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):960-970.e2. PubMed ID: 25151419
[TBL] [Abstract][Full Text] [Related]
8. High-Expenditure Pharmaceutical Use Among Children in Medicaid.
Cohen E; Hall M; Lopert R; Bruen B; Chamberlain LJ; Bardach N; Gedney J; Zima BT; Berry JG
Pediatrics; 2017 Sep; 140(3):. PubMed ID: 28765380
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999-2010.
Soria Saucedo R; Liu X; Hincapie-Castillo JM; Zambrano D; Bussing R; Winterstein AG
Psychiatr Serv; 2018 Aug; 69(8):919-926. PubMed ID: 29879872
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients.
Fontanella CA; Bridge JA; Campo JV
Ann Pharmacother; 2009 Dec; 43(12):1939-47. PubMed ID: 19934394
[TBL] [Abstract][Full Text] [Related]
12. The impact of Medicaid managed care on hospitalizations for ambulatory care sensitive conditions.
Bindman AB; Chattopadhyay A; Osmond DH; Huen W; Bacchetti P
Health Serv Res; 2005 Feb; 40(1):19-38. PubMed ID: 15663700
[TBL] [Abstract][Full Text] [Related]
13. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care.
Martin A; Van Hoof T; Stubbe D; Sherwin T; Scahill L
Psychiatr Serv; 2003 Jan; 54(1):72-7. PubMed ID: 12509670
[TBL] [Abstract][Full Text] [Related]
14. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.
Tulner LR; Kuper IM; Frankfort SV; van Campen JP; Koks CH; Brandjes DP; Beijnen JH
Am J Geriatr Pharmacother; 2009 Apr; 7(2):93-104. PubMed ID: 19447362
[TBL] [Abstract][Full Text] [Related]
15. Prescribing patterns of polypharmacy in Korean pediatric patients.
Jeon SM; Park S; Rhie SJ; Kwon JW
PLoS One; 2019; 14(10):e0222781. PubMed ID: 31574095
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacy and chronic pain: harm exposure is not all about the opioids.
Giummarra MJ; Gibson SJ; Allen AR; Pichler AS; Arnold CA
Pain Med; 2015 Mar; 16(3):472-9. PubMed ID: 25280054
[TBL] [Abstract][Full Text] [Related]
17. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
[TBL] [Abstract][Full Text] [Related]
18. Polypharmacy among medicaid-insured children with and without documented obesity.
Kyler KE; Hall M; Antoon JW; Goldman J; Grijalva CG; Shah SS; Tang Girdwood S; Williams DJ; Feinstein JA
Pharmacotherapy; 2023 Jul; 43(7):588-595. PubMed ID: 36564960
[TBL] [Abstract][Full Text] [Related]
19. Prescribing patterns and predictors of high-level polypharmacy in the elderly population: A prospective surveillance study from two teaching hospitals in India.
Harugeri A; Joseph J; Parthasarathi G; Ramesh M; Guido S
Am J Geriatr Pharmacother; 2010 Jun; 8(3):271-80. PubMed ID: 20624616
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of polypharmacy exposure among hospitalized children in the United States.
Feudtner C; Dai D; Hexem KR; Luan X; Metjian TA
Arch Pediatr Adolesc Med; 2012 Jan; 166(1):9-16. PubMed ID: 21893637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
